Reducing prostate biopsies and magnetic resonance imaging with prostate cancer risk stratification
Open Access
- 22 April 2022
- journal article
- research article
- Published by Wiley in BJUI Compass
- Vol. 3 (5) , 344-353
Abstract
Objectives: To recalibrate and validate the European Randomized Study of Screening for Prostate Cancer risk calculators (ERSPC RCs) 3/4 and the magnetic resonance imaging (MRI)‐ERSPC‐RCs to a contemporary Norwegian setting to reduce upfront prostate multiparametric MRI (mpMRI) and prostate biopsies.Patients and Methods: We retrospectively identified and entered all men who underwent prostate mpMRI and subsequent prostate biopsy between January 2016 and March 2017 in a Norwegian centre into a database. mpMRI was reported using PI‐RADS v2.0 and clinically significant prostate cancer (csPCa) defined as Gleason ≥ 3 + 4. Probabilities of csPCa and any prostate cancer (PCa) on biopsy were calculated by the ERSPC RCs 3/4 and the MRI‐ERSPC‐RC and compared with biopsy results. RCs were then recalibrated to account for differences in prevalence between the development and current cohorts (if indicated), and calibration, discrimination and clinical usefulness assessed.Results: Three hundred and three patients were included. The MRI‐ERSPC‐RCs were perfectly calibrated to our cohort, although the ERSPC RCs 3/4 needed recalibration. Area under the receiver operating curve (AUC) for the ERSPC RCs 3/4 was 0.82 for the discrimination of csPCa and 0.77 for any PCa. The AUC for the MRI‐ERSPC‐RCs was 0.89 for csPCa and 0.85 for any PCa. Decision curve analysis showed clear net benefit for both the ERSPC RCs 3/4 (>2% risk of csPCa threshold to biopsy) and for the MRI‐ERSPC‐RCs (>1% risk of csPCa threshold), with a greater net benefit for the MRI‐RCs. Using a >10% risk of csPCa or 20% risk of any PCa threshold for the ERSPC RCs 3/4, 15.5% of mpMRIs could be omitted, missing 0.8% of csPCa. Using the MRI‐ERSPC‐RCs, 23.4% of biopsies could be omitted with the same threshold, missing 0.8% of csPCa.Conclusion: The ERSPC RCs 3/4 and MRI‐ERSPC‐RCs can considerably reduce both upfront mpMRI and prostate biopsies with little risk of missing csPCa.Keywords
Funding Information
- Norges Forskningsråd (295013)
This publication has 29 references indexed in Scilit:
- Reducing infection rates after prostate biopsyNature Reviews Urology, 2014
- Systematic Review of Complications of Prostate BiopsyEuropean Urology, 2013
- Standards of Reporting for MRI-targeted Biopsy Studies (START) of the Prostate: Recommendations from an International Working GroupEuropean Urology, 2013
- Prediction of Prostate Cancer Risk: The Role of Prostate Volume and Digital Rectal Examination in the ERSPC Risk CalculatorsEuropean Urology, 2012
- Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer Risk Calculators: A Performance Comparison in a Contemporary Screened CohortEuropean Urology, 2010
- Head‐to‐head comparison of two online nomograms for prostate biopsy outcome predictionBJU International, 2010
- Assessing the Performance of Prediction ModelsEpidemiology, 2010
- A Risk-Based Strategy Improves Prostate-Specific Antigen–Driven Detection of Prostate CancerEuropean Urology, 2010
- Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markersBMC Medical Informatics and Decision Making, 2008
- Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention TrialJNCI: Journal of the National Cancer Institute, 2006